Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO756 in Moderate to Severe Chronic Spontaneous Urticaria
2024-518786-10-01Phase 2Completed
- Sponsor
- Evommune
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing EVO756 Potassium dose-ranging with Placebo (2 arms). Primary endpoint: Mean change from baseline in UAS7 at Week 12. Started Jun 2025; status: completed.
02
Drugs
EVO756
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-518786-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518786-10-01.